Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Melanoma 5Crohn Disease 4Colitis, Ulcerative 4Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Inflammatory Bowel Diseases 3Colitis 3Arthritis, Rheumatoid 3Urogenital Neoplasms 2Inflammation 2Hematologic Neoplasms 2Graft vs Host Disease 2Fatigue 2Depressive Disorder, Major 2Depression 2Cachexia 2Anorexia 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Skin Neoplasms 1Recurrence 1Rare Diseases 1Pemphigoid, Benign Mucous Membrane 1Pancreatic Neoplasms 1Lymphoma 1Kidney Transplantation 1Hypertension 1

Interventions

Escitalopram 3Psilocybin 2Interpersonal Psychotherapy 2Infliximab 2Antidepressive Agents 2abacavir 1Venlafaxine Hydrochloride 1Sugars 1Saline Solution 1Mirtazapine 1Ketamine 1Fatty Acids, Omega-3 1Desvenlafaxine Succinate 1Cognitive Behavioral Therapy 1Citalopram 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Depressive Disorder, Major × Infliximab × Clear all
NCT00463580 2025-07-08

Infliximab

Emory University

Phase 4 Completed
60 enrolled 15 charts

Bipolar Disorder, Depression, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant

NCT06136546 2025-05-07

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled

Depression, Depressive Disorder, Major, Inflammation, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡